LXRs activation increases ABCA1 cholesterol transporters and inducible degrader of the low-density lipoprotein receptor (IDOL) in turn triggering low-density lipoprotein receptor (LDLR) degradation and reducing intracellular cholesterol, thereby reducing SREBPs, tumor growth, and survival. This evidence concerns the gene VLDLR and neoplasm.